Point-of-care test sensitivity and specificity, positive predictive value (PPV) and negative predictive value (NPV), per specimen (estimated syphilis prevalence: 12.7%; estimated active syphilis prevalence: 5.1%), according to the assessment of the readers (R1, R2), compared with the lab-based golden standard (TPPA for the treponemal component, RPR for the non-treponemal component)
| Sensitivity (%) | 95% CI | Specificity (%) | 95% CI | PPV (%) | 95% CI | NPV (%) | 95% CI | ||||
| Serum | Bioline | TREP | R1 | 80.0 | 63.1 to 91.6 | 100.0 | 98.6 to 100.0 | 100.0 | 78.5 to 99.9 | 97.2 | 94.6 to 98.4 |
| R2 | 82.9 | 66.4 to 93.4 | 99.6 | 97.8 to 100.0 | 96.8 | 81.0 to 99.5 | 97.6 | 95.1 to 98.8 | |||
| Chembio | TREP | R1 | 57.7 | 36.9 to 76.6 | 99.5 | 97.0 to 100.0 | 93.9 | 68.0 to 99.1 | 94.2 | 91.2 to 96.2 | |
| R2 | 64.0 | 42.5 to 82.0 | 99.4 | 96.9 to 100.0 | 94.4 | 69.9 to 99.2 | 95.0 | 91.8 to 97.0 | |||
| Non-TREP | R1 | 63.6 | 30.8 to 89.1 | 99.5 | 97.2 to 100.0 | 86.8 | 46.9 to 98.0 | 98.1 | 96.0 to 99.1 | ||
| R2 | 63.6 | 30.8 to 89.1 | 99.0 | 96.3 to 99.9 | 76.3 | 43.0 to 93.2 | 98.1 | 95.9 to 99.1 | |||
| Blood | Bioline | TREP | R1 | 51.4 | 34.0 to 68.6 | 100.0 | 98.6 to 100.0 | 100.0 | 70.1 to 99.8 | 93.4 | 91.0 to 95.2 |
| R2 | 54.3 | 36.6 to 71.2 | 100.0 | 98.6 to 100.0 | 100.0 | 71.3 to 99.8 | 93.8 | 91.3 to 95.5 | |||
| Chembio | TREP | R1 | 65.4 | 44.3 to 82.8 | 99.5 | 97.3 to 100.0 | 95.1 | 72.8 to 99.3 | 95.2 | 92.1 to 97.1 | |
| R2 | 69.2 | 48.2 to 85.7 | 99.5 | 97.2 to 100.0 | 95.2 | 73.6 to 99.3 | 95.7 | 92.6 to 97.5 | |||
| Non-TREP | R1 | 63.6 | 30.8 to 89.1 | 100.0 | 98.3 to 100.0 | 100.0 | 46.6 to 99.6 | 98.1 | 96.1 to 99.1 | ||
| R2 | 63.6 | 30.8 to 89.1% | 99.5 | 97.4 to 100.0 | 87.9 | 49.3 to 98.2 | 98.1 | 96.0 to 99.1 |
R1, reader 1; R2, reader 2.